Filing Flows › Emmaus Life Sciences (EMMA) › Q1 2026
Emmaus Life Sciences (EMMA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Emmaus Life Sciences (EMMA) reported revenue of $2.0M for the first quarter 2026 (Q1 2026), -18% from a year earlier and -49% from the quarter before. Operating margin was -41.5%, net loss $3.3M (168.3% of revenue).
Emmaus Life Sciences, Q1 2026: revenue $2.0M (-18% year over year), operating margin -41.5%, net loss $3.3M, operating cash flow −$344K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.0M | -49% | -18% |
| Operating profit | −$823K | -193% | — |
| Net earnings | −$3.3M | — | — |
| Operating cash flow | −$344K | -116% | -223% |
What changed
Revenue was $2.0M in Q1 2026, down 18% year over year and down 49% from the previous quarter. Endari US was the largest line at 69% of revenue. Endari US lost $679K year over year (down 33%), 160% of the total change.
Gross margin was 91.5%, up 0.9 points from Q1 2025. Operating costs exceeded revenue by $823K, an operating margin of -41.5%. Operating expenses fell 17% while revenue fell 18%. The fastest-growing cost line was Sales & marketing (+16%). The quarter ended with a net loss of $3.3M, wider than the previous quarter's $2.0M loss. Net interest and other expense of $2.5M was the main reason.
Operating cash flow was −$344K. Non-cash charges added back $15K of depreciation and $1K of share-based compensation. Working capital and other items added $3.0M.
Questions
What was Emmaus Life Sciences' revenue in the first quarter 2026?
Emmaus Life Sciences (EMMA) reported revenue of $2.0M for the first quarter 2026 (Q1 2026), -18% from a year earlier and -49% from the quarter before.
Was Emmaus Life Sciences profitable in the first quarter 2026?
Operating loss was $823K (-41.5% of revenue) and net loss $3.3M.